Next-generation sequencing-based genomic profiling of advanced soft tissue and bone sarcomas
The high proportion of patients eligible for targeted therapies identified underscores the critical need to integrate NGS-derived genetic insights into clinical practice to improve survival rates and treatment outcomes through more tailored therapeutic approaches for each individual. NGS also led to a reclassification of diagnosis in four patients, demonstrating its utility not only in therapeutic decision-making but also as a powerful diagnostic tool.
Authors
- Recep Çeçen
- Arda Ulaş Mutlu (ORCID: https://orcid.org/0000-0001-7499-7155)
- Yasemin Gündoğdu (ORCID: https://orcid.org/0000-0002-1428-8290)
- Can Boynukara (ORCID: https://orcid.org/0000-0002-6075-3923)
- İbrahim Yıldız (ORCID: https://orcid.org/0000-0001-8525-6280)
- Elif Şenocak Taşçı (ORCID: https://orcid.org/0000-0002-1686-1628)
- Leyla Özer (ORCID: https://orcid.org/0000-0002-1430-2662)
Institutions
- Türkisch-Deutsche Universität (TR)
- Istanbul University-Cerrahpaşa (TR)
- Istanbul Memorial Hospital (TR)
- Istanbul University (TR)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2025-10-03
- DOI
- https://doi.org/10.3389/fonc.2025.1627452
- Citations
- 2
- Primary Topic
- Sarcoma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 3.04